Conditions: Hypertriglyceridemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 114
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 26 weeks in participants with Hypertriglyceridemia.

Detailed description:

Arms:
arm 1: Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks. arm 2: Volanesorsen 300 mg administered subcutaneously once-weekly for 26 weeks. arm 3: Volanesorsen 300 mg administered subcutaneously once-weekly for 13 weeks, then bi-weekly for 13 weeks.

Interventions: intervention 1: Volanesorsen intervention 2: Placebo
Intervention descriptions: intervention 1: 300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks. intervention 2: Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.

Protocol document: